Workflow
心理健康治疗
icon
Search documents
联合国举行非传染性疾病及心理健康高级别会议
Xin Hua She· 2025-09-26 05:49
这份政治宣言草案提出"五年三个1.5亿人"目标:到2030年吸烟人口减少1.5亿人、高血压得到控制 的人口增加1.5亿人、获得心理治疗的人口增加1.5亿人。 在由联合国常务副秘书长阿明娜·穆罕默德代为宣读的会议致辞中,联合国秘书长古特雷斯说,非 传染性疾病和心理疾病对公共卫生和发展构成重大挑战。他敦促各国行动起来,强化医疗、改变人们的 生活方式、促进心理疾病治疗、提供足够资金、重视罹患非传染性疾病和心理疾病的人群、兑现相关承 诺。 贝尔伯克在致辞时说,非传染性疾病导致的死亡中,近四分之三发生在中低收入国家。心理疾病的 治疗方面同样存在不平等,全球人均心理健康年支出仅2美元,而低收入国家不足25美分。她说,据估 计,2011年至2030年的20年间,非传染性疾病将造成全球30万亿美元的经济损失,心理疾病带来的相关 成本与生产力损失将达16万亿美元。 世界卫生组织总干事谭德塞则强调,非传染性疾病和心理疾病可预防、可治疗,当前缺乏的是承 诺、行动速度和规模。他敦促所有国家在促进健康和预防疾病方面增加投资、将非传染性疾病和心理疾 病纳入初级卫生保健、促进医疗平等。 新华社联合国9月25日电(记者尚绪谦)第四次联合国非 ...
Cybin(CYBN) - 2025 FY - Earnings Call Transcript
2025-08-18 15:00
Financial Data and Key Metrics Changes - The company has transitioned to a Phase III company, indicating significant progress in its clinical development [21] - CYB3 demonstrated a 71% remission rate in patients with uncontrolled depression after just two doses in a Phase II study, showcasing a substantial efficacy advantage over standard treatments [24] Business Line Data and Key Metrics Changes - The company is advancing its lead program CYB3, which is in the final stage of development for treating major depressive disorder (MDD) [22] - CYB4, a program for generalized anxiety disorder (GAD), is in a Phase II proof of concept study, with enrollment expected to complete in August 2025 [29] Market Data and Key Metrics Changes - The commercial success of esketamine, with sales of $366 million in the US and $414 million worldwide, reflects a growing market for innovative mental health treatments [32] - The company is witnessing a supportive political and regulatory environment, which is expected to expedite regulatory pathways for psychedelic therapies [31] Company Strategy and Development Direction - The company is focused on executing its clinical programs while preparing for regulatory submissions and commercial manufacturing readiness [28] - Strategic collaborations with Thermo Fisher Scientific and AusMind are aimed at enhancing manufacturing capabilities and supporting commercial preparation [27] Management's Comments on Operating Environment and Future Outlook - The management expressed optimism about the regulatory environment, citing bipartisan support and positive signals from US agencies [31] - The company is well-capitalized and positioned for multiple near-term inflection points in its clinical programs, reinforcing its leadership in the sector [34] Other Important Information - The company has significantly expanded its intellectual property portfolio, now comprising over 100 granted patents and more than 250 pending applications [30] - The EMBRACE study will enroll approximately 330 participants across 60 clinical sites in the US, Europe, and Australia, indicating a robust international research base [26] Q&A Session Summary Question: What is the current status of the clinical programs? - The company is currently in Phase III for CYB3 and expects to have top-line readout in 2026, with ongoing enrollment in the EMBRACE study [28][34] Question: How does the company view the regulatory environment? - Management highlighted a positive shift in the regulatory landscape, with increased support from government officials and agencies, which is expected to benefit the entire sector [31]